skip to main content

HCC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGI CancersHCCSCE Medical Oncology

A fit patient with untreated advanced hepatocellular carcinoma is Child-Pugh A but has recent variceal bleeding, making bevacizumab unsuitable. Which current NICE-funded immunotherapy combination avoids VEGF inhibition?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Durvalumab with tremelimumab

NICE TA1090 makes durvalumab with tremelimumab a routine option for untreated advanced or unresectable HCC. It avoids bevacizumab in a patient with recent variceal bleeding. The alternatives either retain VEGF-pathway treatment, are not the relevant NICE-funded combination, or omit the evidence-based partner.

Reference: NICE TA1090: durvalumab with tremelimumab for untreated advanced HCC. https://www.nice.org.uk/guidance/TA1090/chapter/1-recommendation